JP2016535036A - 消化不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 - Google Patents
消化不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 Download PDFInfo
- Publication number
- JP2016535036A JP2016535036A JP2016526911A JP2016526911A JP2016535036A JP 2016535036 A JP2016535036 A JP 2016535036A JP 2016526911 A JP2016526911 A JP 2016526911A JP 2016526911 A JP2016526911 A JP 2016526911A JP 2016535036 A JP2016535036 A JP 2016535036A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- fat
- monoacylglycerol
- composition
- mag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002759 monoacylglycerols Chemical class 0.000 title claims abstract description 102
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 59
- 201000006549 dyspepsia Diseases 0.000 title claims abstract description 52
- 238000011282 treatment Methods 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 claims abstract description 87
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 41
- 229930195729 fatty acid Natural products 0.000 claims abstract description 41
- 239000000194 fatty acid Substances 0.000 claims abstract description 41
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 30
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 25
- 238000010521 absorption reaction Methods 0.000 claims abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims abstract description 15
- 206010033649 Pancreatitis chronic Diseases 0.000 claims abstract description 15
- 229910003460 diamond Inorganic materials 0.000 claims abstract description 14
- 239000010432 diamond Substances 0.000 claims abstract description 14
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 14
- 206010052765 Pancreatic duct obstruction Diseases 0.000 claims abstract description 13
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 13
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 13
- 208000002720 Malnutrition Diseases 0.000 claims abstract description 11
- 235000018343 nutrient deficiency Nutrition 0.000 claims abstract description 11
- 108010029485 Protein Isoforms Proteins 0.000 claims description 25
- 102000001708 Protein Isoforms Human genes 0.000 claims description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 24
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
- 201000002528 pancreatic cancer Diseases 0.000 claims description 14
- 235000019155 vitamin A Nutrition 0.000 claims description 14
- 239000011719 vitamin A Substances 0.000 claims description 14
- 235000019166 vitamin D Nutrition 0.000 claims description 14
- 239000011710 vitamin D Substances 0.000 claims description 14
- 235000019165 vitamin E Nutrition 0.000 claims description 14
- 239000011709 vitamin E Substances 0.000 claims description 14
- 235000019168 vitamin K Nutrition 0.000 claims description 14
- 239000011712 vitamin K Substances 0.000 claims description 14
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 12
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 12
- 229930003316 Vitamin D Natural products 0.000 claims description 12
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 12
- 229930003448 Vitamin K Natural products 0.000 claims description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 12
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 12
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 12
- 229940046009 vitamin E Drugs 0.000 claims description 12
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 12
- 229940045997 vitamin a Drugs 0.000 claims description 12
- 229940046008 vitamin d Drugs 0.000 claims description 12
- 229940046010 vitamin k Drugs 0.000 claims description 12
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 11
- 235000013734 beta-carotene Nutrition 0.000 claims description 11
- 239000011648 beta-carotene Substances 0.000 claims description 11
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 11
- 229960002747 betacarotene Drugs 0.000 claims description 11
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 11
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- 206010036590 Premature baby Diseases 0.000 claims description 2
- -1 sn-1 (3) MAG Chemical class 0.000 abstract description 6
- 210000000496 pancreas Anatomy 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 44
- 229960001243 orlistat Drugs 0.000 description 25
- 230000029087 digestion Effects 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 19
- 229940002552 xenical Drugs 0.000 description 19
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 18
- 235000021323 fish oil Nutrition 0.000 description 16
- 235000016709 nutrition Nutrition 0.000 description 15
- 230000008901 benefit Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 206010025476 Malabsorption Diseases 0.000 description 9
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 101710098554 Lipase B Proteins 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 231100000762 chronic effect Toxicity 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000006317 isomerization reaction Methods 0.000 description 4
- 208000018773 low birth weight Diseases 0.000 description 4
- 231100000533 low birth weight Toxicity 0.000 description 4
- 235000000824 malnutrition Nutrition 0.000 description 4
- 230000001071 malnutrition Effects 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000011785 micronutrient Substances 0.000 description 4
- 235000013369 micronutrients Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- JDKIKEYFSJUYJZ-OUJQXAOTSA-N (5Z,11Z,14Z,17Z)-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCC\C=C/CCCC(O)=O JDKIKEYFSJUYJZ-OUJQXAOTSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical group CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940040461 lipase Drugs 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 235000015263 low fat diet Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 3
- 208000001162 steatorrhea Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 1
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 description 1
- PRHHYVQTPBEDFE-URZBRJKDSA-N (5Z,11Z,14Z)-icosatrienoic acid Chemical compound CCCCC\C=C/C\C=C/CCCC\C=C/CCCC(O)=O PRHHYVQTPBEDFE-URZBRJKDSA-N 0.000 description 1
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-KBPWROHVSA-N (8E,10E,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C/CCCCCCC(O)=O DQGMPXYVZZCNDQ-KBPWROHVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZQVCBSOYUHORDA-UHFFFAOYSA-N C(CC)OCC(OC(C=CC=CC=CC=CC=CCCCCCCCCC)=O)COCCC.C(C)OCC(OC(C=CC=CC=CC=CC=CCCCCCCCCC)=O)COCC.C(C)(=O)OCC(OC(C=CC=CC=CC=CC=CCCCCCCCCC)=O)COC(C)=O Chemical compound C(CC)OCC(OC(C=CC=CC=CC=CC=CCCCCCCCCC)=O)COCCC.C(C)OCC(OC(C=CC=CC=CC=CC=CCCCCCCCCC)=O)COCC.C(C)(=O)OCC(OC(C=CC=CC=CC=CC=CCCCCCCCCC)=O)COC(C)=O ZQVCBSOYUHORDA-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- DQGMPXYVZZCNDQ-UVZPLDOLSA-N Calendinsaeure Natural products CCCCCC=C/C=C/C=C/CCCCCCC(=O)O DQGMPXYVZZCNDQ-UVZPLDOLSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 102000005311 colipase Human genes 0.000 description 1
- 108020002632 colipase Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pediatric Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
− 出生時体重が1800〜2500gである/であった乳児又は児童(通常、「低出生体重」又はLBWと呼ばれる。)
− 出生時体重が1000〜1800gである/であった乳児又は児童(「極低出生体重」又はVLBWと呼ばれる。)
− 出生時体重が1000g未満である/であった乳児又は児童(「超低出生体重」又はELBWと呼ばれる。)
を包含する。
sn−1(3)−モノエイコサペンタエノイルグリセロール
sn−1(3)−モノドコサヘキサエノイルグリセロール
sn−1(3)−モノオクタデカトリエノイルグリセロール
sn−1(3)−モノオクタデカテトラエノイルグリセロール
sn−1(3)−モノエイコサトリエノイルグリセロール
sn−1(3)−モノドコサペンタエノイルグリセロール
sn−1(3)−モノシアドニルグリセロール(monosciadonylglycerol)
sn−1(3)−モノジュニペロニルグリセロール(monojuniperonylglycerol)
及びそれらの組み合わせが挙げられる。
1,3−ジアセチル−2−エイコサペンタエノイルグリセロール
1,3−ジエチル−2−エイコサペンタエノイルグリセロール
1,3−ジプロピル−2−エイコサペンタエノイルグリセロール
sn−2 モノエイコサペンタエノイルグリセロールのバニリン誘導体
モノエイコサペンタエノイルグリセロールのその他のアセタール誘導体
及びそれらの組み合わせが挙げられる。
[0088]脂質消化不良又は吸収不良のラットモデルにおいてコンセプトを試験した。XENICAL(登録商標)(ORLISTAT)、膵臓、及び胃リパーゼ阻害剤(テトラヒドロリプスタチン;図7参照)を用い、消化不良又は吸収不良状態を得た。ラットには、主にエイコサペンタエン(EPA)酸を含む長鎖多価不飽和脂肪酸(LC−PUFA)補給剤を21日間給餌した。トリアシルグリセロール源として魚油を使用し、様々なEPAグリセリドを評価した。脂質吸収を40%低下させるのに十分な量でXENICAL(登録商標)(ORLISTAT)を投与した。XENICAL(登録商標)(ORLISTAT)は投与せずに魚油を投与した群を陽性対照として使用した。異なる時点(第3日目、第7日目、第14日目、及び第21日目)で、赤血球の脂肪酸プロファイルと、血漿脂質を測定した。試験終了時に、異なる組織の脂肪酸プロファイルを評価した。
この臨床試験では、XENICAL(登録商標)(ORLISTAT)により誘導される脂質消化不良状態下のヒトにおけるEPA送達において、sn−1(3)MAG及び魚油(TAG)の有効性を比較した。BMIが37〜40kg/m2であり、XENICAL(登録商標)(ORLISTAT)で処置して脂質消化不良を誘導したボランティア、あるいはXENICAL(登録商標)(ORLISTAT)で処置していないボランティア、において比較試験を行った。21日間にわたって、魚油(TAG)又はsn−1(3)MAGとして摂取させたときの、EPAの赤血球への蓄積を評価することを第1の目的とした。21日間にわたって血漿におけるEPAの蓄積を評価すること、並びにsn−1(3)MAG又はTAG(接触後10時間のカイロミクロンにおけるAUG)のいずれかの形態での急性投与後に、EPAの薬物動態を評価することを第2の目的とした。図3参照。
[0096]脂質成分の生体可給性を評価するための生体外消化。模倣消化、又は生体外消化は、消化期間(口腔、胃及び小腸)の、脂溶性ビタミン及びカロテノイドなどの脂質成分の安定性、並びに脂質成分の混合胆汁酸塩ミセル画分への分割の程度(脂溶性分子を吸収するのに必須となる工程)を評価するモデルとして使用される。混合胆汁酸塩のミセルへの脂質成分の分割は、「生体可給性」とも呼ばれ、ミセル化効率として表される。各工程において、酵素の種類は必要により適切なものにし(例えば、吸収不良群対対照群)、また目的に適したものとした(例えば、TAG、MAG、ビタミン、カロテノイド)。
Claims (25)
- 消化不良を処置するための方法であって、それを必要とする個体に、モノアシルグリセロール及び脂溶性栄養素を含む治療的に有効な量の組成物を投与することを含む、方法。
- 前記脂溶性栄養素が、脂溶性ビタミン及びカロテノイドからなる群から選択される、請求項1に記載の方法。
- 前記脂溶性栄養素が、ビタミンA、ビタミンAのアイソフォーム、ビタミンD、ビタミンDのアイソフォーム、ビタミンE、ビタミンEのアイソフォーム、ビタミンK、ビタミンKのアイソフォーム、βカロテン、ルテイン、及びそれらの組み合わせからなる群から選択される、請求項1又は2に記載の方法。
- 前記モノアシルグリセロールが、治療的に有効な量のsn−1(3)モノアシルグリセロールを含む、請求項1〜3のいずれか一項に記載の方法。
- 前記モノアシルグリセロールの量が、前記個体における脂肪酸の吸収を促進するのに治療的に有効な量である、請求項1〜4のいずれか一項に記載の方法。
- 前記モノアシルグリセロールの量が、前記個体における前記脂溶性栄養素の送達を増進するのに治療的に有効な量である、請求項1〜5のいずれか一項に記載の方法。
- 前記消化不良が、慢性膵炎、嚢胞性線維症、糖尿病、膵管閉塞、膵腫瘍、シュワックマン・ダイアモンド症候群(SDS)、及びそれらの組み合わせからなる群から選択される状態に伴うものである、請求項1〜6のいずれか一項に記載の方法。
- 前記消化不良の処置が、ビタミン及び多価不飽和脂肪酸(PUFA)の栄養学的欠乏を補正することを含む、請求項1〜7のいずれか一項に記載の方法。
- 前記モノアシルグリセロール(MAG)が、MAG−EPA、MAG−DHA、又はMAG−ARAのうちの少なくとも1種を含む、請求項1〜8のいずれか一項に記載の方法。
- 前記組成物が、前記消化不良により引き起こされるビタミン及び脂肪酸(PUFA)の栄養学的欠乏を補正するのに治療的に有効な量で投与される、請求項1〜9のいずれか一項に記載の方法。
- 前記個体が早産児である、請求項1〜10のいずれか一項に記載の方法。
- モノアシルグリセロール及び脂溶性栄養素を含む治療的に有効な量の組成物を、消化不良のリスクのある個体に投与することを含む、方法。
- 前記脂溶性栄養素が、ビタミンA、ビタミンAのアイソフォーム、ビタミンD、ビタミンDのアイソフォーム、ビタミンE、ビタミンEのアイソフォーム、ビタミンK、ビタミンKのアイソフォーム、カロテノイド、及びそれらの組み合わせからなる群から選択される、請求項12に記載の方法。
- 嚢胞性線維症を処置する方法であって、それを必要とする個体に、sn−1(3)モノアシルグリセロール及び脂溶性栄養素を含む治療的に有効な量の組成物を投与することを含む、方法。
- 糖尿病を処置する方法であって、それを必要とする個体に、sn−1(3)モノアシルグリセロール及び脂溶性栄養素を含む治療的に有効な量の組成物を投与することを含む、方法。
- sn−1(3)モノアシルグリセロール及び脂溶性栄養素を含む組成物であって、前記sn−1(3)モノアシルグリセロールが、消化不良を有する個体における前記脂溶性栄養素の吸収を促進するのに治療的に有効な量で存在する、組成物。
- 前記脂溶性栄養素が、ビタミンA、ビタミンAのアイソフォーム、ビタミンD、ビタミンDのアイソフォーム、ビタミンE、ビタミンEのアイソフォーム、ビタミンK、ビタミンKのアイソフォーム、カロテノイド、及びそれらの組み合わせからなる群から選択される、請求項16に記載の組成物。
- 前記sn−1(3)モノアシルグリセロールが機能性脂肪酸を含み、前記sn−1(3)モノアシルグリセロールが、前記個体における前記機能性脂肪酸の吸収を増進するのに治療的に有効な量で存在する、請求項16又は17に記載の組成物。
- 前記組成物が、嚢胞性線維症を処置するのに治療的に有効なものである、請求項16〜18のいずれか一項に記載の組成物。
- 前記sn−1(3)モノアシルグリセロール及び前記脂溶性栄養素が前記脂溶性栄養素の吸収を相乗的に促進する、請求項16〜19のいずれか一項に記載の組成物。
- 前記sn−1(3)モノアシルグリセロール(MAG)が、MAG−EPA、MAG−DHA、又はMAG−ARAのうちの少なくとも1種を含む、請求項16〜20のいずれか一項に記載の組成物。
- 消化不良状態に罹患している個体における栄養素欠乏の処置における使用のための組成物であって、sn−1(3)モノアシルグリセロール及び脂溶性栄養素を含み、前記モノアシルグリセロールのアシル基が、脂肪酸からなる群から選択される、組成物。
- 前記モノアシルグリセロールのアシル基が、多価不飽和脂肪酸(PUFA)からなる群から選択される、請求項22に記載の組成物。
- 前記sn−1(3)モノアシルグリセロールが、MAG−EPA、MAG−ARA、又はMAG−DHAのうちの少なくとも1種を含む、請求項22又は23に記載の組成物。
- 前記脂溶性栄養素が、脂溶性ビタミン及びカロテノイドからなる群から選択される、請求項22〜24のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361896507P | 2013-10-28 | 2013-10-28 | |
US61/896,507 | 2013-10-28 | ||
PCT/EP2014/073028 WO2015063041A1 (en) | 2013-10-28 | 2014-10-27 | Monoacylglycerols and fat-soluble nutrients for use in the treatment of maldigestion |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016535036A true JP2016535036A (ja) | 2016-11-10 |
Family
ID=51870996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016526911A Pending JP2016535036A (ja) | 2013-10-28 | 2014-10-27 | 消化不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20160279089A1 (ja) |
EP (1) | EP3062789A1 (ja) |
JP (1) | JP2016535036A (ja) |
CN (1) | CN105658216A (ja) |
AU (1) | AU2014343901A1 (ja) |
CA (1) | CA2924004A1 (ja) |
WO (1) | WO2015063041A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020536572A (ja) * | 2017-10-13 | 2020-12-17 | グリコスバイオ フード サイエンシズ,インコーポレーテッド | モノアシルグリセリド油の製造方法、及びモノアシルグリセリド油を含有する食品 |
JP7506658B2 (ja) | 2018-09-21 | 2024-06-26 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 膵外分泌不全(epi)の治療のための栄養組成物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
MA42954A (fr) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals Europe Ltd | Potentialisateurs cftr deutérés |
US11229230B2 (en) | 2016-10-24 | 2022-01-25 | Callion Pharma, Llc | Antioxidant-enriched multivitamin composition and methods of use |
WO2018080591A1 (en) * | 2016-10-27 | 2018-05-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated cftr potentiators |
US20200085774A1 (en) * | 2016-12-23 | 2020-03-19 | Basf As | Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia |
US11582982B2 (en) | 2017-10-13 | 2023-02-21 | Glycosbio Inc. | Method of making monoacylglyceride oils and food products containing monoacylglyceride oils |
US11708331B2 (en) | 2017-12-01 | 2023-07-25 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
AU2019217673A1 (en) | 2018-02-07 | 2020-09-24 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
EP3752304B1 (en) | 2018-02-15 | 2023-10-18 | 5n Plus Inc. | High melting point metal or alloy powders atomization manufacturing processes |
US11166933B2 (en) | 2018-05-03 | 2021-11-09 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007290990A (ja) * | 2006-04-24 | 2007-11-08 | Kao Corp | 食後血中インスリン上昇抑制剤 |
EP2322169A1 (en) * | 2009-11-13 | 2011-05-18 | Laboratorios Casen-Fleet, S.L. | Composition containing a DHA oil for use in the treatment of cystic fibrosis |
WO2012052059A1 (en) * | 2010-10-21 | 2012-04-26 | Swedish Orphan Biovitrum Ab (Publ) | Method to increase the absorption of unsaturated fatty acids by human infants |
EP2508180A1 (en) * | 2011-04-04 | 2012-10-10 | Nestec S.A. | Sn-1(3) Monoacylglycerides and lipid absorption |
JP2013530999A (ja) * | 2010-07-05 | 2013-08-01 | ネステク ソシエテ アノニム | sn−2−モノアシルグリセロール及び脂質吸収不良 |
WO2013123139A1 (en) * | 2012-02-17 | 2013-08-22 | Alcresta, Inc. | Methods, compositions, and devices for supplying dietary fatty acid needs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050074444A1 (en) * | 2003-10-01 | 2005-04-07 | Papas Andreas M. | Coenzyme Q10 treatment for cystic fibrosis |
-
2014
- 2014-10-27 CA CA2924004A patent/CA2924004A1/en not_active Abandoned
- 2014-10-27 US US15/032,861 patent/US20160279089A1/en not_active Abandoned
- 2014-10-27 JP JP2016526911A patent/JP2016535036A/ja active Pending
- 2014-10-27 CN CN201480057840.XA patent/CN105658216A/zh active Pending
- 2014-10-27 WO PCT/EP2014/073028 patent/WO2015063041A1/en active Application Filing
- 2014-10-27 AU AU2014343901A patent/AU2014343901A1/en not_active Abandoned
- 2014-10-27 EP EP14795983.7A patent/EP3062789A1/en not_active Withdrawn
-
2018
- 2018-01-12 US US15/869,701 patent/US20180133190A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007290990A (ja) * | 2006-04-24 | 2007-11-08 | Kao Corp | 食後血中インスリン上昇抑制剤 |
EP2322169A1 (en) * | 2009-11-13 | 2011-05-18 | Laboratorios Casen-Fleet, S.L. | Composition containing a DHA oil for use in the treatment of cystic fibrosis |
JP2013530999A (ja) * | 2010-07-05 | 2013-08-01 | ネステク ソシエテ アノニム | sn−2−モノアシルグリセロール及び脂質吸収不良 |
WO2012052059A1 (en) * | 2010-10-21 | 2012-04-26 | Swedish Orphan Biovitrum Ab (Publ) | Method to increase the absorption of unsaturated fatty acids by human infants |
EP2508180A1 (en) * | 2011-04-04 | 2012-10-10 | Nestec S.A. | Sn-1(3) Monoacylglycerides and lipid absorption |
WO2013123139A1 (en) * | 2012-02-17 | 2013-08-22 | Alcresta, Inc. | Methods, compositions, and devices for supplying dietary fatty acid needs |
Non-Patent Citations (4)
Title |
---|
"Comparison of MAG and Fish Oil Efficacy", CLINICALTRIALS.GOV, vol. NCT01797757, JPN6018028556, 21 February 2013 (2013-02-21) * |
JOURNAL OF PEDIATRICS, vol. 141, no. 2, JPN6018028558, 2002, pages 178 - 185 * |
NUTRIENTS, vol. Vol.4, JPN6018028557, 2012, pages 1781 - 1793 * |
NUTRITION RESEARCH, vol. Vol.30, JPN6018028559, 2010, pages 134 - 140 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020536572A (ja) * | 2017-10-13 | 2020-12-17 | グリコスバイオ フード サイエンシズ,インコーポレーテッド | モノアシルグリセリド油の製造方法、及びモノアシルグリセリド油を含有する食品 |
JP7506658B2 (ja) | 2018-09-21 | 2024-06-26 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 膵外分泌不全(epi)の治療のための栄養組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20160279089A1 (en) | 2016-09-29 |
EP3062789A1 (en) | 2016-09-07 |
CN105658216A (zh) | 2016-06-08 |
CA2924004A1 (en) | 2015-05-07 |
US20180133190A1 (en) | 2018-05-17 |
AU2014343901A1 (en) | 2016-03-17 |
WO2015063041A1 (en) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180133190A1 (en) | Monoacylglycerols and fat-soluble nutrients for use in the treatment of nutrient deficiency from maldigestion | |
US10039742B2 (en) | Sn-2-monoacylglycerols and lipid malabsorption | |
JP6170033B2 (ja) | sn−1(3)モノアシルグリセリド及び脂質吸収 | |
US20160263073A1 (en) | Monoacylglycerols for use in the treatment of malabsorption having a mechanical basis | |
JP2016535037A (ja) | 非機械的基礎を有する吸収不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 | |
JP2022502348A (ja) | 膵外分泌不全(epi)の治療のための組成物及び方法 | |
US10285967B2 (en) | Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190326 |